The Forum offered the WaykiChain team the opportunity to further introduce itself and its services to an international audience. Hang Gao communicated the potential blockchain has to offer in areas like finance and business with leaders in these fields from various countries. He also explained the future benefits of blockchain technology to enterprise innovation.
“Blockchain has a bright future and can bring benefits to every part of a person’s life,” Hang Gao told them. “I believe the next bull market will be triggered by some killer-level Dapps, and hopefully, WaykiChain’s products will be one of them.”
WaykiChain’s product offerings are constantly growing. WaykiChain has rolled out its Developer Incentive Program between January and March of 2019, aiming at enriching and promoting the development of the WaykiChain ecology with developers. On March 22, 2019, WaykiChain also officially launched its DApp, WaykiTime 1.2.0. The management and technical team continues to develop the product line thanks to its rich experience and international background. After the CDF, WaykiChain hopes to further extend its international market and create closer ties with overseas partners.
WaykiChain (WICC) is a third-generation blockchain that is based on DPoS consensus algorithms and supports Turing-complete smart contracts. It is able to sustain transactional throughput above 1,000 TPS in actual use. In the long run, WaykiChain (WICC) aims to provide a secure, reliable and high-performance blockchain technology platform that will enable the growth of multiple industries such as prediction markets, decentralized assets exchanges, and decentralized forex exchanges.
Follow WaykiChain’s official channels for the latest updates:
Developer Telegram Group: https://wicc.me/g2
English Telegram Group: https://wicc.me/pr8
For inquiries, please contact: email@example.com
Results presented at Foundation for Angelman Syndrome Therapeutics (FAST) Global SummitAdditional data, including EEG findings, support prior initial indications of activity and there were no
NORTH CHICAGO, Ill., Dec. 5, 2020 /PRNewswire/ — AbbVie (NYSE: ABBV) today announced new data from the Phase 2 CAPTIVATE (PCYC-1142) clinical trial evaluating IMBRUVICA® (ibrutinib)
“MCL patients who have been treated with a covalent BTK inhibitor have very few therapeutic options, and outcomes are extremely poor. LOXO-305 has demonstrated a
WASHINGTON, Dec. 5, 2020 /PRNewswire/ — Three studies being presented during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition report promising results in
Long-term follow-up data from the phase III MURANO trial showed sustained progression-free survival with fixed-duration Venclexta/Venclyxto plus MabThera/RituxanMURANO and phase III CLL14 trials confirm chronic
NORTH CHICAGO, Ill., Dec. 5, 2020 /PRNewswire/ — AbbVie (NYSE: ABBV) today announced new, updated results from the Phase 3 MURANO and CLL14 clinical trials